IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (Nasdaq: SCYX) concerning possible violations of federal securities laws.
If you purchased shares of SCYNEXIS, and want more information free of charge, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
SCYNEXIS announced that the U.S. Food and Drug Administration ("FDA") has issued a hold on clinical trials for the intravenous formulation of the Company’s lead product candidate SCY-078 “until the FDA completes a review of all available pre-clinical and clinical data.”
SCYNEXIS told investors that “[t]he clinical hold decision was issued by the FDA following a review of three mild-to-moderate thrombotic events in healthy volunteers receiving the IV formulation of SCY-078 at the highest doses and highest concentrations in a Phase 1 study.”
When this information was revealed to shareholders, the value of SCYNEXIS fell, causing investors harm.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.